Newbury Pharmaceuticals AB (publ) (STO:NEWBRY)
Sweden · Delayed Price · Currency is SEK 1.100
-0.075 (-6.38%)
Feb 10, 2026, 5:22 PM CET
STO:NEWBRY Revenue
Newbury Pharmaceuticals AB had revenue of 11.72M SEK in the quarter ending November 30, 2025, with 79.26% growth. This brings the company's revenue in the last twelve months to 36.76M, up 14.21% year-over-year. In the fiscal year ending August 31, 2025, Newbury Pharmaceuticals AB had annual revenue of 31.57M, down -14.27%.
Revenue (ttm)
36.76M
Revenue Growth
+14.21%
P/S Ratio
0.91
Revenue / Employee
4.59M
Employees
8
Market Cap
33.44M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Aug 31, 2025 | 31.57M | -5.26M | -14.27% |
| Aug 31, 2024 | 36.83M | 26.56M | 258.75% |
| Aug 31, 2023 | 10.27M | 4.75M | 86.11% |
| Aug 31, 2022 | 5.52M | 2.43M | 78.73% |
| Aug 31, 2021 | 3.09M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EQL Pharma AB | 425.75M |
| Enzymatica AB | 52.73M |
| Cinclus Pharma Holding AB | 48.42M |
| Nanexa AB | 31.92M |
| Orexo AB | 26.00M |
| Moberg Pharma AB | 12.50M |
| Klaria Pharma Holding AB (publ.) | 10.05M |
| Enorama Pharma AB | 3.63M |